Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HG146 in Relapsed/Refractory Multiple Myeloma
NCT03710915Phase 1Terminated
- Sponsor
- HitGen
- Start
- Jan 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HG146 in multiple myeloma (MM), sponsored by HitGen. Primary endpoint: Maximum Tolerated Dose at 3 months. Started Jan 2019; status: terminated.
02
Drugs
HG146
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03710915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710915.